Our leadership team

David P. King is a respected senior healthcare executive who operates with a strong emphasis on deeply understanding the healthcare industry, strategic planning, and staying ahead of rapidly evolving industry trends and challenges.  

David served for over 13 years as Executive Chair and CEO of Laboratory Corporation of America Holdings (Labcorp). Under his leadership, Labcorp transformed from a pure-play U.S. testing laboratory into a leading global life sciences company — tripling in size through a combination of organic growth and strategic acquisitions. 

In 2019, Forbes named David to its list of America’s Most Innovative Leaders. His Board service includes positions as Non-Executive Chair of Privia Health (NASDAQ:PRVA) and Non-Executive Chair of ZimVie (NASDAQ:ZIMV) and he also serves on several private boards. 

David holds a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School. 

Euan was appointed President and Chief Executive Officer in September 2021. He initially joined LGC as a Non-Executive Director from 2007 to 2010, before taking up an Executive role as Corporate Development Director in July 2010. In 2012, he was appointed Managing Director of the Standards division and built LGC’s wider Quality Assurance business over the following eight years.

Euan has been an Executive Director on the Board since 2017 and was appointed President and Chief Operating Officer in June 2020.

Euan joined LGC from the UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to that, Euan spent the early part of his career in business strategy consulting and corporate finance. Euan is a graduate of University College, Oxford.

Marcus Kaeller was appointed Chief Financial Officer in June 2024. He was previously Group CFO and Managing Director of Affidea, a leading European diagnostic imaging and healthcare services provider. Marcus has also held senior financial leadership roles at Laureate Education, Stryker, and AstraZeneca, and began his career at Unilever and Accenture.  

He holds an undergraduate degree in Business Administration and Economics from Edinburgh University, is a Qualified Accountant with the Chartered Institute of Management Accountants in London and has an MBA from London Business School. 

Nicolas joined the Board of LGC in April 2016. Prior to joining the Group, Nicolas served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group (2009 to 2013) and Vice President and General Manager of the Life Sciences Division (2006 to 2009). 

Prior to joining Agilent Technologies Inc., Nicolas was with Bio-Rad Laboratories, Inc. and served as the Life Science Group’s Group Operations Officer, heading five business divisions spanning life science and food science. Between 2001 and 2002, Nicolas was Vice President of Marketing, Sales and Business Development at Strategene and then served as Chief Operating Officer from 2003 to 2005. 

Professionally, Nicolas is currently a Venture Partner with Sciety AB, and advisor PE firms and serves on several public and private BODs.  

Tish joined the Board of LGC in August 2020. 

Prior to joining the Group, Tish served as the Executive Vice President of Applied Solutions Strategy, Marketing and Innovation (SMI) for MilliporeSigma, a Merck KGaA Company. Before the acquisition of Sigma-Aldrich by Merck KGaA, Tish was part of Sigma-Aldrich from 2005 – 2015 and served as Vice President of the Diagnostics & Testing team as well as Vice President of the Global Custom Products business focused on oligonucleotides and peptides. 

From 1999 to 2005, Tish was with Applied Biosystems serving as Director, R&D Proteomics & Small Molecule Division with a focus on mass spectrometry.  

Tish is the recipient of several scientific achievement awards and is a published author of both scientific articles and patents. She completed her PhD in Organic Chemistry at Pennsylvania State University. 

Supraj joined Cinven in 2004 he and manages the day-to-day operations of the firm as CEO and chairs the Executive Committee. 

Over the years he has worked on a number of transactions, including Ahlsell, Barentz, CeramTec, Clario (formerly Bioclinica), JLA, Medpace, National Seating & Mobility, Phadia, Sebia and STADA. Previously, he was at The Boston Consulting Group, where he worked on projects in the healthcare and financial services sectors. 

Supraj graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences. 

Matthew joined Cinven in 2010 and is a member of its Healthcare sector team. He has been involved in several transactions, including BioAgilytix, Medpace, NPS, Pronet, Sebia, STADA, Labco and Synlab (merged under the Synlab brand), Envirotainer and Ufinet.

Prior to joining Cinven, Matthew worked in the Investment Banking Division of Citigroup in London, advising on M&A and restructuring deals across a range of sectors including consumer, real estate, TMT and healthcare.

Matthew graduated from Imperial College London with a Master’s Degree in Physics.

François is Chief Investment Officer of Astorg, Conducting Officer of AAM in Luxembourg, Managing Partner and Legal Representative of AAM in Luxembourg. He is a member of the Board of Directors of Wendel, as well as of Wendel-Participations SE, the leading family shareholder of the Wendel group. 

François started his career at CCF in the M&A division in Milan, then, in 1991, joined the Acquisition & Leveraged Finance team at Société Générale. In 1997, he joined Intermediate Capital Group PLC, leading arranger and provider of mezzanine finance for LBO transactions in Europe and listed on the London stock exchange. He was appointed Managing Director in 2005, then progressively responsible for ICG’s investment activities in Mezzanine and Equity in Europe and worldwide. 

François joined Astorg in 2012. He is a graduate of IEP Paris and Université de Dauphine Paris IX. 

James joined Astorg in 2019. He leads the Business Services team and is a member of the Flagship Fund Investment Committee.

Prior to this, he spent 20 years at Intermediate Capital Group (ICG) where he was Managing Director responsible for investments in the Nordic Region and a member of the Investment Committee. James started his career at Deloitte where he qualified as a chartered accountant.

He is a graduate of Oxford University. 

James is a Portfolio Manager in Abu Dhabi Investment Authority (ADIA)’s EMEA Private Equities Department and joined in 2019.

Prior to joining ADIA, James worked in investment banking within JP Morgan’s Healthcare team in London and at Credit Suisse in Sydney.

James is a graduate of The University of Melbourne.  

Bharathi joined SeraCare in 2000, which was later acquired by LGC. She was appointed Executive Vice President of LGC’s Diagnostics & Genomics Innovation Hub in April 2024.  

Previously, she served as Senior Vice President of Product Development and Technical Operations and later as Executive Vice President and General Manager of LGC Clinical Diagnostics. Before joining SeraCare, Bharathi was the lead scientist at DNA Technologies, where she developed molecular assays and managed contract manufacturing.  

She has over 25 years of experience in technology and product development across infectious diseases, oncology, genetic diseases, and recombinant viruses.  

Bharathi holds a PhD in Microbiology from Osmania University, India. 

Ken is Executive Vice President and General Manager for Diagnostics & Genomics at LGC. He joined the Company in September 2022 as EVP and GM for LGC’s Standards business.

Before LGC, Ken co-founded Fortis Life Sciences where he served as Chief Operating Officer. He has also held senior executive roles at Millipore Sigma, worked as a management consultant for McKinsey and Company, and as a postdoctoral fellow at the Novartis Institute for Biomedical Research. Ken holds a PhD in Neuroscience from Yale University and a BS with Honors in Chemistry from Stanford University. 

Bruno brings over 28 years of global experience in the life sciences industry, including the laboratory, pharmaceutical, and diagnostic market segments. He has held senior roles in product management, sales and marketing, R&D, operations, and process excellence.

Before joining LGC, Bruno held leadership positions at Leica Microsystems, Millipore, and most recently served as CCO at Olink Proteomics. He holds a Master’s degree in Organic Chemistry from École Nationale Supérieure de Chimie de Clermont-Ferrand (ENSCCF). 

Sanjeev was appointed Executive Vice President and General Manager, Corporate Development, Assure and NLS in May 2024. He joined LGC in 2019 and served as Senior Vice President, Corporate Strategy, Development, and Communications.

Prior to joining LGC, Sanjeev held senior executive roles at Hesira, Danaher, and UBS.

He holds a Bachelors degree in Chemistry from the University of East Anglia and is a qualified Chartered Accountant. 

Alex joined LGC as Executive Vice President & General Manager for Axolabs in August 2024. 

Alex most recently served as Vice President & Global Business Unit Head, Innovator Products & Solutions at Johnson Matthey (a CDMO business). Prior to this role, he held a range of senior commercial leadership roles at Lonza AG, VWR (part of Avantor) and Sigma-Aldrich. Alex started his career working as a scientist in the pharmaceutical industry. 

With a HBSc and MSc from the University of Toronto, Alex also holds a doctorate in molecular biology from the International Max-Planck Research School at the University of Marburg, Germany. 

Julie joined LGC in August 2022 as Chief People Officer.

She has held a variety of HR leadership roles, including senior positions at Maersk, Horizon Discovery Plc, Getronics, CPA Global, bringing both private equity and listed company experience in a range of sectors.

Julie holds a Bachelor’s degree in Ancient History and Archaeology and a Master’s in Contemporary Japan.

Lee joined LGC in July 2021 as Chief Technology Officer and became Chief Digital and Information Officer in July 2022.

Prior to LGC, Lee worked at Walgreens Boots Alliance, leading Global IT Services and Programmes, including supporting retailers during the COVID-19 pandemic. He also had an extensive career at GlaxoSmithKline, covering infrastructure, enterprise platforms, and corporate business services.

Lee holds a Bachelor’s degree in Business and Computing and a Post Graduate Diploma in Strategy and Innovation from Oxford Saïd Business School. He is currently pursuing a Master’s level qualification in Artificial Intelligence at the University of Oxford.

With over 25 years of legal experience, Helen has held senior global roles at leading multinational companies, including Vodafone and Cable & Wireless.

Prior to joining LGC, she was Legal Director for both Vodafone’s Internet of Things (IoT) business and for Vodafone’s Strategy and M&A Board. Helen has extensive Environmental, Social & Governance (ESG) experience from her time as Company Secretary for Vodafone Group’s ESG Committee.

She holds an undergraduate degree in Natural Sciences from Cambridge University and is a Chartered Company Secretary.   

Manjeet joined LGC in April 2021 as Chief Digital and Information Officer and was appointed Chief Transformation Officer in July 2022.

Following his service with the Royal Air Force, Manjeet had an extensive career in pharmaceuticals with GlaxoSmithKline, where he led global technology functions across pharmaceutical and vaccine verticals. He also has significant experience managing enterprise-wide business transformation programmes.

Manjeet holds a Bachelor’s degree in Engineering and a Diploma in Accounting and Finance.